title: Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
authors.affiliation: Division of Cardiovascular Medicine, Stanford University, Stanford, California.
authors.forename: Fatima
authors.initials: F
authors.lastname: Rodriguez
authors.affiliation: Division of Cardiovascular Medicine, Stanford University, Stanford, California2Department of Medicine, Stanford University, Stanford, California.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D055118:Medication Adherence; D000091362:PCSK9 Inhibitors; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D000071449:Proprotein Convertase 9
chemical_list: D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9